Table 1 Prevalence of ESBL-producing, blaCTX-M, blaSHV, and blaTEM-positive, class 1 and class 2 integrons-positive, MDR, and antibiotic-resistant E. coli among the studied isolatesa
From: Risk of sharing resistant bacteria and/or resistance elements between dogs and their owners
Characteristics | In all isolates (n = 144) | In dog’s isolates (n = 56) | In owner’s isolates (n = 56) | In control’s isolates (n = 32) |
|---|---|---|---|---|
ESBL-producing | 19 (13.2) | 6 (10.7) | 11 (19.6) | 2 (6.2) |
blaCTX-M-positive | 21 (14.6) | 7 (12.5) | 12 (21.4) | 2 (6.2) |
blaSHV-positive | 7 (4.9) | 4 (7.1) | 1 (1.8) | 2 (6.2) |
blaTEM-positive | 61 (42.4) | 24 (42.9) | 25 (44.6) | 12 (37.5) |
Class 1 integron-positive | 52 (36.1) | 23 (41.1) | 22 (39.3) | 7 (21.9) |
Class 2 integron-positive | 16 (11.1) | 4 (7.1) | 7 (12.5) | 5 (15.6) |
MDR | 42 (29.2) | 23 (41.1) | 13 (23.2) | 6 (18.8) |
Cephalexin-resistant | 19 (13.2) | 5 (8.9) | 12 (21.4) | 2 (6.2) |
Cefoxitin-resistant | 1 (0.7) | 0 (0.0) | 1 (1.8) | 0 (0.0) |
Ceftazidime-resistant | 29 (20.1) | 12 (21.4) | 15 (26.8) | 2 (6.2) |
Cefotaxime-resistant | 46 (31.9) | 20 (35.7) | 22 (39.3) | 4 (12.5) |
Cefepime-resistant | 19 (13.2) | 8 (14.3) | 9 (16.1) | 2 (6.2) |
Aztreonam-resistant | 9 (6.2) | 4 (7.1) | 5 (8.9) | 0 (0.0) |
Amikacin-resistant | 7 (4.9) | 3 (5.4) | 4 (7.1) | 0 (0.0) |
Streptomycin-resistant | 60 (41.7) | 27 (48.2) | 21 (37.5) | 12 (37.5) |
Norfloxacin-resistant | 5 (3.5) | 5 (8.9) | 0 (0.0) | 0 (0.0) |
Nalidixic acid-resistant | 37 (25.7) | 8 (14.3) | 14 (25.0) | 15 (46.9) |
Chloramphenicol-resistant | 20 (13.9) | 13 (23.2) | 3 (5.4) | 4 (12.5) |
Tetracycline-resistant | 56 (38.9) | 30 (53.6) | 17 (30.4) | 9 (28.1) |